Drugmakers compete to launch treatments for blood clots

08/30/2010 | New York Times (tiered subscription model), The

Several companies are racing to develop anti-coagulants to replace warfarin for patients with an increased risk of stroke and blood clots. Experimental anti-clotting drugs apixaban and rivaroxaban are thought to have potential in stroke prevention.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA